Somatostatinoma is a malignant tumor of the delta cells of the endocrine pancreas that produces somatostatin. Increased levels of somatostatin inhibit pancreatic hormones and gastrointestinal hormones. Thus somatostatinomas are associated with mild diabetes mellitus (due to inhibition of insulin release), steatorrhoea and gallstones (due to inhibition of cholecystokinin release), and achlorhydria (due to inhibition of gastrin release). Somatostatinomas are commonly found in head of pancreas.
In a normal subject actions of somatostatin include:
- In the anterior pituitary gland, the effects of somatostatin are:
- Somatostatin suppresses the release of gastrointestinal hormones
- Lowers the rate of gastric emptying, and reduces smooth muscle contractions and blood flow within the intestine
- Suppresses the release of pancreatic hormones
- Suppresses the exocrine secretory action of pancreas.
This explains how abnormally elevated somatostatin can cause diabetes mellitus, by inhibiting insulin secretion, steatorrhoea by inhibiting cholecystokinin and secretin, gall stones by inhibiting cholecystokinin which normally induce gallbladder myocytes to contract, and hypochlorhydria caused by inhibiting gastrin, which normally stimulate acid secretion.
Somatostatinomas are associated with calcium deposits called psammoma bodies.
This section is empty. You can help by adding to it. (November 2017)
Fasting plasma somatostatin greater than 30 pg/mL.
SRS(Somatostatin Receptor Scintigraphy)- It is a radio-nucleotide scan by giving Octreotide tagged with Indium111 isotope, which shows an increase in uptake by the tumour cells.
Treatment is by chemotherapy with streptozocin, dacarbazine, doxorubicin or by 'watchful waiting' and surgical debulking via Whipple procedure and other resections of the gastrointestinal organs affected.